en · de · es · pt
assay-notes.peptides4800.com › Data › Mechanism And Evidence Base — Research Overview

Mechanism And Evidence Base — Research Overview

By Editorial Desk · published 2026-02-17 · last reviewed 2026-03-28 · Data

If you have been reading about tuftsin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-28. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Evidence Base

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

Selank at a glance

PropertyValueNotes
Route studiedIntranasalPredominant route in published reports
Circulation stabilityShort, minutes scalePeptidases cleave it; the tail slows the process
Analytical methodRP-HPLC with mass spectrometryUsed for identity and purity assessment
Reported outcome domainsAnxiety and cognitive measuresDerived from small, mostly regional trials
Regulatory statusMarketed in RussiaAvailability outside that market is limited

Origins and Proposed Mechanisms

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Related pages on this site

Analytical Methods and Stability

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Analytical Methods And Storage Stability

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Storage, Analysis, and Regulatory Status

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Reference notes

== History == Founded in 1972, the company was originally known as Bio Medical Data, Inc. until the early 1980s, when it changed its name to Doctor's Data. It was originally owned by Miller Pharmacal, which was founded by John J. Miller, former research chemist for J.B. Roerig, which was purchased in 1953 by Pfizer. Miller died in 1977, and three owners took control of the company with Ted Lueken as president.

== Upcoming Peptide Facility == Neuland Laboratories is set to commission a new commercial peptide manufacturing facility at its 17- acre Bonthapally manufacturing campus in the summer of 2026. The project is part of a phased expansion, with additional capacity planned in line with growing client demand. The first of four modules is expected to be operational by mid-2026, adding commercial scale capabilities to its existing peptide manufacturing infrastructure. The new peptide manufacturing facility will feature digitalized operations supported by distributed control system (DCS) automation and electronic batch‑record platforms. It is also designed with expanded purification and drying infrastructure, including multi‑column preparative HPLC systems, large‑scale lyophilizers, enhanced solvent‑handling capabilities, and upgraded waste‑management processes. These features are intended to support consistent batch quality and more efficient production cycles.

== Function == Natural articular cartilage is an inhomogeneous, anisotropic, and viscoelastic tissue. The structure, described above 1.1.2. allows the cartilaginous tissue to have superior mechanical properties in order to perform the functions necessary. Synthetic cartilage will attempt to mimic the functional properties of natural cartilage, which can be broken down into two main aspects.

Coninae Fleming, 1822 — synonyms: Conulinae Rafinesque, 1815 (inv.); Textiliinae da Motta, 1995 (n.a.) Clathurellinae H. Adams & A. Adams, 1858 — synonyms: Defranciinae Gray, 1853 (inv.); Borsoniinae A. Bellardi, 1875; Pseudotominae A. Bellardi, 1888; Diptychomitrinae L. Bellardi, 1888; Mitrolumnidae Sacco, 1904; Mitromorphinae Casey, 1904; Lorinae Thiele, 1925 Conorbiinae de Gregorio, 1880—synonym: Cryptoconinae Cossmann, 1896 Mangeliinae P. Fischer, 1883—synonym: Cytharinae Thiele, 1929 Oenopotinae Bogdanov, 1987—synonym: Lorinae Thiele, 1925 sensu Thiele Raphitominae A. Bellardi, 1875—synonyms: Daphnellinae Casey, 1904; Taraninae Casey, 1904; Thatcheriidae Powell, 1942; Pleurotomellinae F. Nordsieck, 1968; Andoniinae Vera-Pelaez, 2002 † Siphopsinae Le Renard, 1995

==== Educator tax deduction ==== Previously, educators could take a tax deduction for unreimbursed education costs of up to $300 per year (or $600 if married filing jointly) without itemizing their tax deductions. Effective January 1, 2026, eligible educators may also take an itemized tax deduction for unreimbursed education costs in excess of $300 per year (or $600 if married filing jointly). In order to qualify, the individual must work at any K–12 school for least 900 hours during the school year as a teacher, instructor, counselor, principal, aide, interscholastic sports coach, or sports administrator. The unreimbursed education costs must be directly related to the individual's work as an educator. Eligible unreimbursed education costs include books, supplies, other classroom materials, equipment, professional development courses or training that is related to the curriculum or student instruction.

Sources: en.wikipedia.org

Notes from published material

== Applications == Kojic acid may be used on cut fruits to prevent oxidative browning, in seafood to preserve pink and red colors, and in cosmetics to lighten skin.As an example of the latter, it is used to treat skin diseases like melasma. Kojic acid also has antibacterial and antifungal properties. It is also used in the pharmaceutical industry. It is a precursor to the flavorant maltol.

== External links == Kier Lab Swartz Lab Center for Biologically Inspired Design at Georgia Tech Functional Morphology and Biomechanics Laboratory, Brown University Whole Skin Locomotion Inspired Research for this Wikipedia entry was conducted as a part of a Locomotion Neuromechanics course (APPH 6232) offered in the School of Applied Physiology at Georgia Tech Archived 2011-07-19 at the Wayback Machine

In addition, Gaboon vipers produce the most painful bite of any venomous snake in the world. A bite causes very rapid and conspicuous swelling, intense pain, severe shock and local blistering. Other symptoms may include uncoordinated movements, defecation, urination, swelling of the tongue and eyelids, convulsions and unconsciousness. Blistering, bruising and necrosis is often very extensive. There may be sudden hypotension, heart damage and dyspnoea. The blood may become incoagulable with internal bleeding that may lead to haematuria and haematemesis. Local tissue damage may require surgical excision and possibly amputation. Healing may be slow and fatalities during the recovery period are not uncommon.

The Rhodesian Minister for Justice and Law and Order, Desmond Lardner-Burke, presented the rest of the Cabinet with a draft for the declaration of independence on 5 November 1965. When Jack Howman, Minister of Tourism and Information, said that he was also preparing a draft, the Cabinet decided to wait to see his version too. The ministers agreed that if an independence proclamation were issued, they would all sign it. On 9 November, the Cabinet jointly devised an outline for the proclamation document and the accompanying statement to be made by Smith. The final version of the declaration of independence was prepared by a sub-committee of civil servants headed by Gerald Clarke, the Cabinet Secretary, with the United States Declaration of Independence of 1776, the only other such proclamation ever issued by British colonials, used as a model. Strongly alluding to Thomas Jefferson's text throughout, the Rhodesians used one phrase verbatim—"a respect for the opinions of mankind"—but no reference was made to the assertion that "all men are created equal", nor to the "consent of the governed", two omissions later stressed by a number of commentators. Attached to the declaration of independence was a copy of the 1961 constitution amended for the circumstances, which became the 1965 constitution. In the eyes of the Smith administration, this document removed Whitehall's remaining authority over Rhodesia and made Rhodesia a de jure independent state.

=== Lawsuits === From 2019 to 2024, Maria Francesca Gioia, a former medical student acting as a pro se plaintiff, filed nine product liability lawsuits against Janssen Pharmaceuticals and related parties. She alleged that taking Invega Sustenna (paliperidone palmitate) caused her memory loss, hypothyroidism, Horner's syndrome, nerve damage, motor tremors, vocal tics, confusion, loss of taste and sensation, post-traumatic stress disorder, and metabolic syndrome (including hypertension, diabetes, and stroke), which ended her career as a primary care physician. All nine lawsuits were dismissed on procedural grounds: Gioia I–II for failure to state a claim, Gioia III for failure to prosecute, and Gioia IV–V for lack of subject matter jurisdiction. The court also noted that the side effects she alleged were already listed on Invega's FDA-approved warning label. In September 2024, Cassandra Fameux filed a criminal complaint alleging that her husband, a Michigan anesthesiologist, had forcibly injected her with unprescribed Invega Sustenna on multiple occasions between 2017 and 2021. A subsequent police investigation led to a recommendation that he be charged with domestic assault. In May and June 2022, Adilah Patton, a 28‑year‑old pretrial detainee in Indianapolis, was forcibly injected twice with unprescribed Invega Sustenna while in custody at the Marion County Adult Detention Center. A federal lawsuit filed on her behalf alleges that the injections were administered without a medical assessment, a prescription, or the consent of her court‑appointed guardian.

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.

How is Selank typically given in studies?

Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.

How strong is the clinical evidence?

Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Network